Q: Hi folks,
Do you see ATE's bought deal positively because the company is setting the stage for Phase 3 development, or negatively because the company has yet to attract big pharma interest? Would you consider the current price weakness a buying opportunity or just another dilution?
Thanks,
Glen
Do you see ATE's bought deal positively because the company is setting the stage for Phase 3 development, or negatively because the company has yet to attract big pharma interest? Would you consider the current price weakness a buying opportunity or just another dilution?
Thanks,
Glen